General Announcement::Glenmark Pharmaceuticals receives ANDA approval for Ranolazine Extended-Release Tablets

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
09-Jul-2019 11:16:32
Status
New
Announcement Sub Title
Glenmark Pharmaceuticals receives ANDA approval for Ranolazine Extended-Release Tablets
Announcement Reference
SG190709OTHRKECL
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
09/07/2019 00:00:00
Description (Please provide a detailed description of the event in the box below)
Glenmark Pharmaceuticals receives ANDA approval for Ranolazine Extended-Release Tablets, 500 mg and 1,000 mg

Attachments

SGX_PR_09072019 SIGNED.pdf
Total size =3590K